01—Abstract
Summary
Summary of the 8-K filed June 27, 2025. Cited figures are marked; the original filing is the authoritative source.
On June 26, 2025, Incyte Corporation announced that Hervé Hoppenot retired as President and Chief Executive Officer effective that day.
He will continue as a member of the Board of Directors and, under a Transition Agreement dated June 26, 2025, will serve as special advisor to the CEO for the first anniversary of the Effective Date, followed by one year as a non-employee consultant. Julian C. Baker, Lead Independent Director, assumed the role of Chairman of the Board effective June 26, 2025.
The Company also announced that William J. Meury was appointed President and Chief Executive Officer and to the Board, effective June 26, 2025. Mr. Meury previously served as President and CEO of Anthos Therapeutics, Inc. (April 2024 until its acquisition by Novartis in April 2025) and as President and CEO of Karuna Therapeutics, Inc. (January 2023 through March 2024).
His offer letter provides an initial annual base salary of $1,250,000,a a bonus funding target of 100% of base salary, and a sign-on performance share award with a target of 125,000 shares that can be earned at 0-400% of target based on stock price performance. The filing also discloses that the Board increased the shares authorized under the 2024 Inducement Stock Incentive Plan from 1,000,000 to 2,000,000 and removed the 2.0-for-1 share counting provision for full-value awards. Severance terms for Mr. Meury include 1.5 times base salary plus target bonus outside a change in control and 2 times that amount within the 24-month change in control period.
02—Key points
Key Highlights
- Hervé Hoppenot retired as President and CEO effective June 26, 2025, and remains on the Board of Directors.
- Julian C. Baker, Lead Independent Director, assumed the role of Chairman of the Board effective June 26, 2025.
- William J. Meury was appointed President, CEO and Board member effective June 26, 2025; he previously led Anthos Therapeutics and Karuna Therapeutics.
- Mr. Meury's initial annual base salary is $1,250,000, with a bonus funding target of 100% of base salary.
- Mr. Meury's sign-on performance share award has a target of 125,000 shares, earnable at 0-400% of target based on stock price performance.
- Mr. Hoppenot's Transition Agreement provides base salary compensation at $1,395,731 annually for six months, then 50% of that rate for the following six months, plus a prorated 2025 bonus.
- The 2024 Inducement Stock Incentive Plan share authorization was increased from 1,000,000 to 2,000,000 shares.
03—Questions
Frequently Asked Questions
Who is leading Incyte following the CEO change?
William J. Meury became President and Chief Executive Officer effective June 26, 2025, and was also appointed to the Board. He previously served as CEO of Anthos Therapeutics and Karuna Therapeutics.
What role will former CEO Hervé Hoppenot play going forward?
Mr. Hoppenot will remain on the Board and serve as special advisor to the CEO under a Transition Agreement. His employment continues until the first anniversary of June 26, 2025, or an earlier date, after which he will serve as a non-employee consultant for one year.
What compensation does the new CEO receive?
Mr. Meury's offer letter provides an initial annual base salary of $1,250,000 and a bonus funding target of 100% of base salary, prorated for 2025. He also receives a regular annual award of RSUs for 36,101 shares, options for 110,630 shares, a performance share target of 108,303 shares, and a sign-on performance share target of 125,000 shares.
What severance protections does Mr. Meury have?
Outside a change in control period, termination without Cause or for Good Reason results in 1.5 times the sum of base salary and target bonus, plus benefits. Within the 24-month change in control period, the amount is two times that sum, with full vesting of unvested RSUs and options.
Why was the Inducement Plan amended?
The Board amended the 2024 Inducement Stock Incentive Plan to increase authorized shares from 1,000,000 to 2,000,000 before Mr. Meury's equity grants became effective, and removed the provision counting full-value awards as 2.0 shares per share issued.
04—Continue